PMID- 37284198
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230608
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed 
      and refractory multiple myeloma with severe complications.
PG  - 1185991
LID - 10.3389/fonc.2023.1185991 [doi]
LID - 1185991
AB  - BACKGROUND/OBJECTIVE: We retrospectively analyzed the effective and safety of 
      continuous low-dose cyclophosphamide combined with prednisone (CP) in relapsed 
      and refractory multiple myeloma (RRMM) patients with severe complications. 
      METHODS: A total of 130 RRMM patients with severe complications were enrolled in 
      this study, among which 41 patients were further given bortezomib, lenalidomide, 
      thalidomide or ixazomib on the basis of CP regimen (CP+X group). The response to 
      therapy, adverse events (AEs), overall survival (OS) and progression-free 
      survival (PFS) were recorded. RESULTS: Among the 130 patients, 128 patients 
      received therapeutic response assessment, with a complete remission rate (CRR) 
      and objective response rate (ORR) of 4.7% and 58.6%, respectively. The median OS 
      and PFS time were (38.0 +/- 3.6) and (22.9+/-5.2) months, respectively. The most 
      common AEs were hyperglycemia (7.7%), pneumonia (6.2%) and Cushing's syndrome 
      (5.4%). In addition, we found the pro-BNP/BNP level was obviously decreased while 
      the LVEF (left ventricular ejection fraction) was increased in RRMM patients 
      following CP treatment as compared with those before treatment. Furthermore, CP+X 
      regimen further improved the CRR compared with that before receiving the CP+X 
      regimen (24.4% vs. 2.4%, P=0.007). Also, both the OS and PFS rates were 
      significantly elevated in patients received CP+X regimen following CP regimen as 
      compared with the patients received CP regimen only. CONCLUSION: This study 
      demonstrates the metronomic chemotherapy regimen of CP is effective to RRMM 
      patients with severe complications.
CI  - Copyright (c) 2023 Shi, Wei, Peng, Chen, Zhou, Wu, Yu, Zhao, Hou and Zhou.
FAU - Shi, Haotian
AU  - Shi H
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Wei, Wei
AU  - Wei W
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Peng, Rong
AU  - Peng R
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Chen, Haimin
AU  - Chen H
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Zhou, Nian
AU  - Zhou N
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Wu, Lixia
AU  - Wu L
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Yu, Wenjun
AU  - Yu W
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Zhao, Wenhao
AU  - Zhao W
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
FAU - Hou, Jian
AU  - Hou J
AD  - Department of Hematology, Renji Hospital Affiliated to the School of Medicine, 
      Shanghai Jiaotong University, Shanghai, China.
FAU - Zhou, Fan
AU  - Zhou F
AD  - Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an 
      District, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20230522
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10240086
OTO - NOTNLM
OT  - RRMM
OT  - cyclophosphamide
OT  - prednisone
OT  - response to therapy
OT  - safety
OT  - survival
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/07 13:10
MHDA- 2023/06/07 13:11
PMCR- 2023/01/01
CRDT- 2023/06/07 09:44
PHST- 2023/03/14 00:00 [received]
PHST- 2023/05/05 00:00 [accepted]
PHST- 2023/06/07 13:11 [medline]
PHST- 2023/06/07 13:10 [pubmed]
PHST- 2023/06/07 09:44 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1185991 [doi]
PST - epublish
SO  - Front Oncol. 2023 May 22;13:1185991. doi: 10.3389/fonc.2023.1185991. eCollection 
      2023.